-+ 0.00%
-+ 0.00%
-+ 0.00%

Forbion leads Sling Therapeutics USD 123 million Series C round

PUBT·09/16/2026 11:17:45
Listen to the news
Forbion leads Sling Therapeutics USD 123 million Series C round
  • Sling Therapeutics closed a USD 123 million Series C round led by Forbion Capital Partners Management Services BV.
  • Ann Arbor-based Sling develops linsitinib, an oral small-molecule IGF-1R inhibitor for thyroid eye disease.
  • Proceeds earmarked for Phase 3 development, including the global ORBIT pivotal trial in adults with moderate to severe active TED.
  • TPG Life Sciences Innovations participated as an existing investor; Sectoral Asset Management joined as a new investor.
  • Linsitinib holds U.S. FDA Fast Track designation for thyroid eye disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.